The study highlights the current progress in the development of coumarin scaffolds for drug discovery as novel anticancer agents in metastatic breast cancer. Eight compounds, combining the coumarin core and five membered heterocycles (isoxazoles and thiazoles) in hydrazinyldiene- -chroman-2,4-diones, were characterized in terms of a potential antiproliferative effect on bone (SCP1833) and lung (SCP4175) metastatic breast cancer cell lines using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Cell viability was evaluated after 48 and 72 h of treatment and the 50 % inhibitory concentrations were determined. The results demonstrated dose- and time-dependent activity, with the most potent molecules having a thiazole moiety, without or with additional methyl group(s) attached to the carbon(s) at position(s) 5 and/or 4 in the thiazole ring. These molecules possessed significantly higher potency against both test cell lines compared to 4-hydroxycoumarin
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. A. Lacy and R. O’Kennedy Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer Cur. Pharm. Des. 10 (2004) 3797-3811; DOI: 10.2174/1381612043382693.
2. M. E. Marshall M. Ryles K. Butler and L. Weiss Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: longterm follow-up of patients treated on a phase I trial J. Cancer Res. Clin. Oncol. 120 (1994) 535-538.
3. U. S. Weber B. Steff en and C. P. Siegers Antitumour-activities of coumarin 7-hydroxycoumarin and its glucuronide in several human tumour cell lines Res. Commun. Mol. Pathol. Pharmacol. 99 (1998) 193-206.
4. M. A. Velasco-Velazquez J. Agramonte-Hevia D. Barrera A. Jimenez-Orozco M. J. Garcia-Mondragon N. Mendoza-Patino A. Landa and J. Mandoki 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts decreasing their adhesion to extracellular matrix proteins and motility Cancer Le_ . 198 (2003) 179-186; DOI: 10.1016/S0304-3835(03)00333-1.
5. S. Stanchev G. Momekov F. Jensen and I. Manolov Synthesis computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives Eur. J. Med. Chem. 43 (2008) 694-706; DOI: 10.1016/j.ejmech.2007.05.005.
6. J. L. Mohler L. G. Gomella E. D. Crawford L. M. Glode C. D. Zippe W. R. Fair and M. E. Marshall Phase II evaluation of coumarin (12-benzopyrone) in metastatic prostatic carcinoma Prostate 20 (1992) 123-131.
7. F. H. Dexeus C. J. Logothetis A. Sella K. Fitz R. Amato J. M. Reuben and N. Dozier Phase II study of coumarin and cimetidine in patients with metastatic renal-cell carcinoma J. Clin. Oncol. 8 (1990) 325-329.
8. D. Cooke Studies on the Mode of Action of Coumarins (Coumarin 6-Hydroxycoumarin 7-Hydroxycoumarin and Esculetin) at a Cellular Level Ph. D. Thesis Dublin City University Dublin 1999; h_ p:// doras.dcu.ie/18438/1/Deirdre_A_Cooke.pdf; last access date March 10 2014.
9. F. Jimenez-Orozco J. S. Lopez-Gonzalez A. Nieto-Rodriguez M. A. Velasco-Velazquez J. A. Molina- Guarneros N. Mendoza-Patino M. J. Garica-Mondragon P. Elizalde-Galvan F. Leon-Cedeno and J. J. Mandoki Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin Lung Cancer 34 (2001) 185-194.
10. M. A. Musa J. S. Cooperwood and M. O. F. Khan A review of cumarin derivatives in pharmacotherapy of breast cancer Cur. Med. Chem. 15 (2008) 2664-2679; DOI: 10.2174/092986708786242877.
11. H. A. Assi K. E. Khoury H. Dbouk L. E. Khalil T. H. Mouhieddine and N. S. El Saghir Epidemiology and prognosis of breast cancer in young women J. Thorac. Dis. 5 (2013) S2-S8; DOI: 10.3978/j. issn.2072-1439.2013.05.24.
12. Y-H. Hsiao M-C. Chou C. Flower J. T. Mason and Y-G. Man Breast cancer heterogeneity: mechanisms proofs and implications J. Cancer 1 (2010) 6-13; DOI: 10.7150/jca.1.6.
13. Y. G. Man and H. E. Nieburgs A subset of cell clusters with malignant features in morphologically normal and hyperplastic breast tissues Cancer Detect. Prev. 30 (2006) 239-247; DOI: 10.1016/j. cdp.2006.04.006.
14. P. Clezardin Therapeutic targets for bone metastases in breast cancer Breast Cancer Res. 13 (2011) 207-215; DOI: 10.1186/bcr2835.
15. M. C. Ravnan S. L. Ravnan and M. P. Walberg Metastatic breast cancer: a review of current and novel pharmacotherapy Formulary 46 (2011) 130-146.
16. F. Cardoso E. Senkus-Kone_ a L. Fallowfi eld A. Costa and M. Castigilone Locally recurrent or metastatic breast cancer: ESMO Clinical practice guidelines for diagnosis treatment and followup Ann. Oncol. 21 (2010) v15-v19; DOI: 10.1093/annonc/mdq160.
17. O. Pagani E. Senkus W. Wood M. Colleoni T. Cufer S. Kyriakides A. Costa E. P. Winer and F. Cardoso International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J. Natl. Cancer Inst. 102 (2010) 456-463; DOI: 10.1093/jnci/djq029.18.
18. A. Jashari F. Imeri L. Ballazhi A. Shabani B. Mikhova G. Drager E. Popovski and A. Huwiler Synthesis and cellular characterization of novel isoxazolo- and thiazolohydrazinyldiene-chroman-24-diones on cancer and non-cancer cell growth and death Bioorg. Med. Chem. 22 (2014) 2655-2661; DOI: 10.1016/j.bmc.2014.03.026.19.K.
19. K. Tabakovic I. Tabakovic M. Trkovnik and N. Trinajstic Chemistry of coumarins. Nucleophilic substitutions of 4-chloro-3-nitrocoumarin with hard and so_ nucleophiles Liebigs Ann. Chem. 11 (1983) 1901-1909; DOI: 10.1002/jlac.198319831105.
20. M. M. Ramla M. A. Omar A. M. M. El-Khamry and H. L. El-Diwan Synthesis and antitumour activity of 1-substituted-2-methyl-5-nitrobenzimidazoles Bioorg. Med. Chem. 14 (2006) 7324-7332; DOI: 10.1016/j.bmc.2006.06.033.
21. E. Gulsory and N. U. Guzeldemirci Synthesis and primary cytotoxicity evaluation of new imidazo[ 21-b]thiazole derivatives Eur. J. Med. Chem. 42 (2007) 320-326; DOI: 10.1016/j.ejmech. 2006.10.012.
22. M. J. Choi E. S. No D. A. Thorat J. W. Jang H. Yang J. Lee H. Choo S. J. Kim C. S. Lee S. Y. Ko J. Lee G. Nam and A. N. Pae Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy J. Med. Chem. 56 (2013) 9008-9018; DOI: 10.1021/jm400840p.
23. P. Poma M. Notarbartolo M. Labbozze_ a A. Maurici V. Carina Alaimo M. Rizzi D. Simoni and N. D’Alessandro The antitumour activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis Int. J. Mol. Med. 20 (2007) 329-335; DOI: 10.3892/ ĳ mm.20.3.329.
24. M. S. Al-Said M. S. Bashandy S. I. Al-qasoumi and M. M. Ghorab Anti-breast cancer activity of some novel 12-dihydropyridine thiophene and thiazole derivatives Eur. J. Med. Chem. 46 (2011) 137-141; DOI: 10.1016/j.ejmech.2010.10.024.
25. M. I. Soares A. F. Brito M. Laranjo A. M. Abrantes M. F. Botelho J. A. Paixao A. M. Beja M. R. Silva E. Pinho and T. M. Melo Chiral 6-hydroxymethyl-1H3H-pyrrolo[12-c]thiazoles: novel antitumour DNA monoalkylating agents Eur. J. Med. Chem. 45 (2010) 4676-4681; DOI: 10.1016/j.ejmech. 2010.07.029.
26. P. Chene C. Garcia-Echeverria M. R. Jensen C. Quadt T. Radimerski and J. Schoepfer Isoxasole compound for the treatment of cancer Patent WO 2009047323 A2 16 April 2009.
27. Y. Kang P. M. Siegel W. Shu M. Drobnjak S. M. Kakonen C. Cordon-Cardo T. A. Guise and J. Massague A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 (2003) 537-549; DOI: 10.1016/S1535-6108(03)00132-6.
28. A. J. Minn G. P. Gupta P. M. Siegel P. D. Bos W. P. Shu D. D. Giri A. Viale A. B. Olshen W. L. Gerald and J. Massague Genes that mediate breast cancer metastasis to lung Nature 436 (2005) 518-524; DOI: 10.1038/nature03799.29.
29. A. Jashari E. Hey-Hawkins B. Mikhova G. Draeger and E. Popovski An improved synthesis of 4-chlorocoumarin-3-sulfonyl chloride and its reactions with diff erent bidentae nucleophiles to give pyrido[1’2’:23]- and thiazino[3’2’:23]-124-thiadiazino[65-c]Benzopyran-6-one 77-dioxides Molecules 12 (2007) 2017-2028; DOI: 10.3390/12082017.
30. A. Jashari E. Popovski B. Mikhova R. P. Nikolova and B. L. Shivachev 3-[2-(5-tert-butyl-12-oxazol-3-yl)hydrazinylidene] chroman-24-dione Acta Crystalogr. E 69 (2013) o258; DOI: 10.1107/ S1600536813000858.